IC9 CAR.19 is under clinical development by Bellicum Pharmaceuticals and currently in Phase I for Splenic Marginal Zone B-Cell Lymphoma. According to GlobalData, Phase I drugs for Splenic Marginal Zone B-Cell Lymphoma have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how IC9 CAR.19’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IC9 CAR.19 overview
iC9 CAR.19 is under investigation for the treatment of relapsed/refractory b-cell acute lymphoblastic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, nodal marginal zone B -cell lymphoma, splenic marginal zone B -cell lymphoma, extranodal marginal zone B-cell lymphoma (mucosa-associated lymphoid tissue or malt-lymphoma), primary mediastinal B-cell lymphoma and mantle cell lymphoma. It is administered through intravenous route. It constitutes chimeric antigen receptor (CAR) T cells which target CD19 protein expressed on cancer cells. AP1903 is administered to activate the iC9-CAR19 safety switch by inducing caspase9 in case of cytokine release syndrome.
See Also:
Bellicum Pharmaceuticals overview
Bellicum Pharmaceuticals, Inc. (Bellicum) is a clinical-stage biopharmaceutical company, that develops cellular immunotherapies for the treatment of cancer. The company develops its product candidates through its chemical induction of dimerization technology platforms in the areas of cellular immunotherapy including hematopoietic stem cell transplantation, CAR T cell therapy and TCR cell therapies. Its GoCAR™ technology builts a enhance effector cell proliferation and functional persistence and is designed to enlist wider immune cell engagement to target resistant tumor cells. Bellicum’s lead pipeline candidate includes BPX-501, an adjunct T-cell therapy intended for the treatment of leukemias, lymphomas and genetic blood diseases. The company also develops pipeline products for the treatment of solid tumors, hematological cancers and others. Bellicum is headquartered in Houston, Texas, the US.
For a complete picture of IC9 CAR.19’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
